anipharmaceuticals.com (ANIP): Price-to-Projected Revenue Ratio
ANI Pharmaceuticals (ANIP) asset protection is based on FDA licenses and proprietary manufacturing plants, which curbs competition. Analyzing the expected P/S value in GURU.Markets, we note that the current parameter is 0.70. This confirms the effectiveness of the strategy to release scarce medications and complex generics. Business stability is further complemented by strict environmental control of synthesis and the sustainable use of water resources.
Financial and market metric breakdowns for ANI Pharmaceuticals Corp (ANIP)
- current price and projected stock value:
- stock exchange capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
Debt to Equity ANI Pharmaceuticals|ANIP - Long-Term Liabilities to Equity|Short-Term Debt to Capital ANI Pharmaceuticals|ANIP - Aggregate Debt Obligations|Debts to Book Capitalization ANI Pharmaceuticals Corp|ANIP - Company Long-Term Debts|Company Short-Term Debt ANI Pharmaceuticals|Quick Liquidity anipharmaceuticals.com
- financial results and valuation multiples details:
ANIP - Net Income|Projected Future Earnings ANI Pharmaceuticals|ANIP - P/E Multiple|Forward P/E Multiple ANI Pharma|ANIP - Price/Earnings to Growth Multiple|EV/EBITDA Multiple ANI Pharmaceuticals Corp|ANIP - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months ANI Pharmaceuticals|ANIP - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months anipharmaceuticals.com|ANIP - Net earnings per one share growth for the current year|Earnings growth forecast for next year ANI Pharmaceuticals
- sales volume and revenue indicators:
Summary company analysis:ANI Pharmaceuticals, Inc. ANIP
The forward P/S ratio assesses the market value of ANI Pharmaceuticals relative to expected revenue, allowing investors to filter out market noise and identify any actual overpayment for the asset. Given the patent protection of ANI Pharmaceuticals formulas, changes in the forward P/S reflect the business's ability to convert regulatory barriers into a stable cash flow, determining the long-term sustainability of the invested capital.
Competitors of ANI Pharmaceuticals
Forward P/S Multiple HLN (Haleon)|Forward P/S Multiple Kenvue Inc KVUE|VRNA - Price-to-Projected Revenue Ratio|MENS (Jyong Bio) - Market Cap to Projected Revenue|LGND: Forward P/S Multiple|AMRX - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PRGO|ALVO: Forward Price to Sales|Price-to-Projected Revenue Ratio Liquidia Technologies (LQDA)|GLPG: Future Price to Revenue|Forward P/S Multiple MNKD (MannKind Corporation)|Forward Price to Sales AMPH|Pacira BioSciences, Inc. - Forward P/S Multiple|SPRY - Forward P/S Multiple|Theravance (TBPH) - Price-to-Projected Revenue Ratio|Aquestive Corp - Forward Price to Sales|Price-to-Projected Revenue Ratio scPharmaceuticals, Inc.|Forward Price-to-Revenue Multiple Tectonic (TECX)|Forward P/S Multiple TNXP|Forward P/S Multiple sxtchina.com (SXTC)|Forward P/S Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|BHST - Forward Price-to-Revenue Multiple|eXoZymes Inc - Forward P/S Multiple|Market Cap to Future Revenue Ratio Oramed Pharmaceuticals|ENTX (enterabio.com) - Forward Price-to-Revenue Multiple|MindWalk Holdings, Inc. (HYFT) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ABVC|CPIX (Cumberland Corp) - Price to Expected Revenue Ratio|Forward P/S Multiple QNTM|Market Cap to Expected Sales Ratio fibrogen.com|Forward P/S Multiple TELO (Telomir Pharmaceuticals, Inc.)|RANI - Forward Price-to-Revenue Multiple|Synergy CHC Corporation - Forward P/S Multiple|RLYB - Forward P/S Multiple|lexariabioscience.com (LEXX) - Price-to-Projected Revenue Ratio|PULM (pulmatrix.com) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Pheton Holdings Limited|Aptorum (APM) - Market Cap to Expected Sales Ratio|Forward P/S Multiple LYRA|Forward P/S Multiple Impact BioMedical, Inc. (IBO)|Price-to-Projected Revenue Ratio TNF Pharmaceuticals, Inc. TNFA|YCBD: Market Cap to Projected Revenue|PainReform - Forward P/S Multiple|Market Cap to Expected Sales Ratio Altamira Therapeutics CYTO|Lipella (LIPO) - Price-to-Projected Revenue Ratio|Future Price to Revenue OPTN (OptiNose Corp)|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals|procapsgroup.com - Future Price to Revenue|Forward P/S Multiple PTPI|QLI (Qilian International Holding Group) - Forward Price to Sales|Forward P/S Multiple SLRN (ACELYRIN, Inc.)|Forward P/S Multiple TFF Pharmaceuticals, Inc TFFP
